Development and validation of an HPLC-DAD method for bis(12)-hupyridone and its application to a pharmacokinetic study
- 20 February 2009
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 49 (2), 410-414
- https://doi.org/10.1016/j.jpba.2008.11.013
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Huperzine A exhibits anti‐inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemiaJournal of Neurochemistry, 2008
- Development of Bivalent Acetylcholinesterase Inhibitors as Potential Therapeutic Drugs for Alzheimers DiseaseCurrent Pharmaceutical Design, 2004
- Acetylcholinesterase Complexed with Bivalent Ligands Related to Huperzine A: Experimental Evidence for Species-Dependent Protein−Ligand ComplementarityJournal of the American Chemical Society, 2002
- Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmineEuropean Journal of Pharmacology, 2002
- Dimerization of an Inactive Fragment of Huperzine A Produces a Drug with Twice the Potency of the Natural ProductAngewandte Chemie-International Edition, 2000
- Pharmacological Profile of Huperzine A, a Novel Acetylcholinesterase Inhibitor from Chinese HerbCNS Drug Reviews, 1999
- Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapyPublished by American Medical Association (AMA) ,1997
- Huperzine A, a novel promising acetylcholinesterase inhibitorNeuroReport, 1996
- Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the ratJournal of Neuroscience Research, 1989
- The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activityCanadian Journal of Chemistry, 1986